Pharmacological approaches to target type 2 cytokines in asthma.
Allergy
Antibody
Asthma
Benralizumab
DARPin
Dupilumab
Interleukin
Mepolizumab
Reslizumab
Tezepelumab
Vaccine
Journal
Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
05
12
2021
revised:
17
02
2022
accepted:
07
03
2022
pubmed:
15
3
2022
medline:
17
8
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
Asthma is the most common chronic lung disease, affecting more than 250 million people worldwide. The heterogeneity of asthma phenotypes represents a challenge for adequate assessment and treatment of the disease. However, approximately 50% of asthma patients present with chronic type 2 inflammation initiated by alarmins, such as IL-33 and thymic stromal lymphopoietin (TSLP), and driven by the T
Identifiants
pubmed: 35283171
pii: S0163-7258(22)00061-4
doi: 10.1016/j.pharmthera.2022.108167
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Cytokines
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108167Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest L.G. has been an investigator in clinical trials for AstraZeneca, MSD and Novartis, reports grants or fees for consulting from AstraZeneca, GlaxoSmithKline, Novartis and Sanofi-Regeneron and fees for consulting from ALK, Bayer, Chiesi, MSD, not related to the submitted work. E.C reports a patent related to asthma and allergy therapy, WO2019228674 (A1). L.L.R. reports grants or fees for consulting from Argenx, Novartis and Neovacs, as well as patents issued or pending related to asthma and allergy diagnosis or therapy: EP20315224-4, WO2019197607 (A1) and WO2019228674 (A1).